✦ LIBER ✦

Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic HER2-Positive Breast Cancer

✍ Scribed by Wilks, Sharon; Puhalla, Shannon; O'Shaughnessy, Joyce; Schwartzberg, Lee; Berrak, Erhan; Song, James; Cox, David; Vahdat, Linda

Book ID: 124121239
Publisher: CIG Media Group, LP.
Year: 2014
Tongue: English
Weight: 169 KB
Volume: 14
Category: Article
ISSN: 1526-8209
DOI: 10.1016/j.clbc.2014.04.004

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase 2 study of eribulin mesylate as fi

Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer

✍ McIntyre, Kristi; O’Shaughnessy, Joyce; Schwartzberg, Lee; Glück, Stefan; Berrak 📂 Article 📅 2014 🏛 Springer US 🌐 English ⚖ 405 KB

Erratum to: Phase 2 study of eribulin me

Erratum to: Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer

✍ McIntyre, Kristi; O’Shaughnessy, Joyce; Schwartzberg, Lee; Glück, Stefan; Berrak 📂 Article 📅 2014 🏛 Springer US 🌐 English ⚖ 127 KB

Trastuzumab plus docetaxel with or witho

Trastuzumab plus docetaxel with or without capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer: a randomised Phase II study

✍ A. Wardlev; A. Anton-Torres; X. Pivot; F. Morales-Vasquez; L. Zetina; M. de Fati 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 69 KB

AVEREL: A Randomized Phase III Trial Eva

AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer

✍ Gianni, Luca (author);Romieu, Gilles H. (author);Lichinitser, Michail (author);S 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 205 KB

AVEREL: A Randomized Phase III Trial Eva

AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer

✍ Gianni, Luca (author);Romieu, Gilles H. (author);Lichinitser, Michail (author);S 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 205 KB

An exploratory study of sunitinib in com

An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer

✍ Fatima Cardoso; Jean-Luc Canon; Dino Amadori; Daniela Aldrighetti; Jean-Pascal M 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 383 KB